Book a demo

Chemical intelligence powered by cypris.ai

FH535

2,5-dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide · also: N-(2-Methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonamide, 2,5-dichloro-N-(2-methyl-4-nitrophenyl)-benzenesulfonamide, 2,5-dichloro-N-(2-methyl-4-nitro-phenyl)benzenesulfonamide, Benzenesulfonamide, 2,5-dichloro-N-(2-methyl-4-nitrophenyl)-, 2,5-dichloro-N-(2-methyl-4-nitrophenyl)benzene-1-sulfonamide

FormulaC13H10Cl2N2O4S
Mol. weight361.193
PubChem CID3463933
InChIKeyAXNUEXXEQGQWPA-UHFFFAOYSA-N
SMILESCC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C2=C(C=CC(=C2)Cl)Cl
298Patents
51Research papers
161Patents - last 3 years
3Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Fujifilm Cellular Dynamics Inc25
2United States Department of Health and Human Services19
3Leland Stanford Junior University18
4Cincinnati Children's Hospital Medical Center14
5Kyoto University8
6RIKEN8
7ABS Global Inc6
8Centre National de la Recherche Scientifique6
9Sumitomo Pharma Co Ltd6
10Massachusetts Institute of Technology5

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1C12NMicroorganisms, enzymes209
2A61KMedicinal preparations163
3A61PTherapeutic activity (drug indications)129
4G01NInvestigating / analysing materials65
5C07KPeptides43
6A61LSterilising / disinfecting materials29
7C12QMeasuring/testing involving enzymes24
8Y02AClimate change adaptation17
9C08LPolymer compositions (blends)12
10A01K9

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Application of FH535 as medicine for promoting differentiation of ADSCs into liver cells2024The First Affiliated Hospital Of Xinjiang Medical University0

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Spine and Intervertebral Disc Pathology1
2Wnt/β-catenin signaling in development and cancer1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Brett T. SpearUniversity of Kentucky5
2Roberto GedalyUniversity of Kentucky5
3Changguo ChenUniversity of Kentucky3
4Chunming LiuUniversity of Kentucky3
5David S. WattUniversity of Kentucky3
6Jieyun JiangUniversity of Kentucky3
7Lilia TurciosUniversity of Kentucky3
8Addolorata Maria Luce ColucciaUniversity of Salento2
9Alexis GrandeUniversity of Modena and Reggio Emilia2
10Antonio ColucciaUniversity of Salento2

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of FH535?

FH535 has the molecular formula C13H10Cl2N2O4S and a molecular weight of 361.193 g/mol. Its canonical chemical name is 2,5-dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide.

Which organizations hold the most patents involving FH535?

The leading patent assignees for FH535 are Fujifilm Cellular Dynamics Inc with 25 patents, United States Department of Health and Human Services with 19 patents, and Leland Stanford Junior University with 18 patents.

What research topics are associated with FH535?

FH535 research is primarily associated with Wnt/β-catenin signaling in development and cancer. Published work covers applications including blockade of Wnt/β-catenin signaling in breast cancer metastasis, targeting of Wnt/β-catenin signaling in liver cancer stem cells and hepatocellular carcinoma, and effects on neural stem cell proliferation and differentiation.

What are the major patent classification areas for FH535-related technology?

FH535 patents are predominantly classified under C12N (biotechnology) with 209 patents, A61K (medicinal preparations) with 163 patents, and A61P (specific therapeutic activity of chemical compounds) with 129 patents. These classifications indicate a focus on pharmaceutical and biotechnological applications.

How has patent activity for FH535 trended in recent years?

Patent filing activity has increased substantially, with 2 patents filed in 2016, rising to 80 patents in 2024. The three-year period prior to the data snapshot shows 161 patents filed, with 2022 having 63 patents, 2023 having 72 patents, and 2024 having 80 patents, indicating accelerating interest.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial